Australia Expands PBS Listing of Zolgensma on 15 November: Eligible Children With Spinal Muscular Atrophy Up to 21 Kilograms, Treatment Costs Over 2.5 Million Dollars Without Subsidy

The Australian Government announced on 15 November that it is giving more young children access to a life-changing gene therapy for spinal muscular atrophy, through an expanded listing of Zolgensma on the Pharmaceutical Benefits Scheme (PBS).
From 1 November 2026, access to Zolgensma (onasemnogene abeparvovec) has been expanded from babies up to 9 months to eligible children up to 21 kilograms in weight. Spinal muscular atrophy is a rare inherited genetic condition that affects the motor neurons controlling muscle movement, causing progressive muscle weakness and wasting, and in its most severe forms paralysis and death. One in 35 Australians unknowingly carry the gene and one in 10,000 babies born in the country is affected.
Zolgensma is a one-time gene therapy designed to address the underlying genetic cause by delivering a functional copy of the SMN1 gene. Without PBS subsidy, the treatment could cost patients more than 2.5 million dollars. It is expected up to five children will benefit from the listing each year, and the government said it has now funded over 500 new and amended PBS listings since July 2022.
Minister for Health Mark Butler said Zolgensma is a one-off, transformative treatment, timing is critical, and at a cost of over 2.5 million dollars it is out of reach for families, adding that the government is making the treatment available and affordable for more families.
Published by GSM · USA (original Chinese edition)
Photo: Wikimedia Commons, File:Parliament House at dusk, Canberra ACT.jpg — Author: Thennicke. Licensing: Creative Commons Attribution-Share Alike 4.0 (CC BY-SA 4.0).